Proton magnetic resonance spectroscopy of the hippocampus in patients with mild cognitive impairment: A pilot study

Journal of Computer Assisted Tomography

Volumn 31, Issue 5, 2007, Pages 666-670

  Franczak, Malgorzata ^a   Prost, Robert W ^a   Antuono, Piero G ^a   Mark, Leighton P ^a   Jones, Jennifer L ^a   Ulmer, John L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Alzheimer disease; Magnetic resonance spectroscopy; Mild cognitive impairment

Indexed keywords

AMINO ACIDS; MAGNETISM; NEURODEGENERATIVE DISEASES; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ALZHEIMERS DISEASE; BRAIN METABOLITES; COGNITIVE IMPAIRMENT; CONTROL SUBJECT; MEASUREMENTS OF; MILD COGNITIVE IMPAIRMENT; MYO-INOSITOL; N-ACETYL ASPARTATE; PILOT STUDIES; PROTON MAGNETIC RESONANCE SPECTROSCOPIES;

METABOLITES;

BIOLOGICAL MARKER; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID;

ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEMENTIA; HIPPOCAMPUS; HUMAN; MEASUREMENT; PILOT STUDY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 34748817512     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e318031bc31     Document Type: Article

References (48)

1. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment. Arch Neurol. 1999;56:303-308.
2. Daly E, Zaitchik D, Copeland M, et al. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. 2000;57:675-680.
3. Grundman M, Petersen R, Morris J, et al. Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment. Neurology. 1996;46(suppl):A403.
4. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41:1006-1009.
5. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358-368.
6. Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46:707-719.
7. Kordower J, Chu Y, Stebbins G, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001;49:202-213.
8. Sherwin BB. Mild cognitive impairment: potential pharmacological options. J Am Geriatr Soc. 2000;48:431-441.
9. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397-1403.
10. Kaye JA, Swihart T, Howieson D, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology. 1997;48:1297-1304.
11. Wolf H, Jelic V, Gertz H-J, et al. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:52-76.
12. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord. 1995;9:6-16.
13. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imag. 2005;32:486-510.
14. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulated cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94.
15. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the [epsilon]4 allele for apolipoprotein E. N Engl J Med. 1996;334:752-758.
16. Rose S, de Zubicaray G, Wang D, et al. A 1H MRS study of probable Alzheimer's disease and normal aging; implications for longitudinal monitoring of dementia progression. Magn Reson Imaging. 1999;17:291-299.
17. Rai G, McConnell J, Waldman A, et al. Brain proton spectroscopy in dementia: an aid to clinical diagnosis. Lancet. 1999;353:1063-1064.
18. Schuff N, Amend DL, Ezekiel F, et al. Changes of hippocampal N-acetylaspartate and volume in Alzheimer's disease: a proton MR spectroscopic imaging and MRI study. Neurology. 1997;49:1513-1521.
19. Miller BL, Moats RA, Shonk T, et al. Alzheimer disease: depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology. 1993;187:443-447.
20. Godbolt AK, Waldman AD, Macmanus DG, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology. 2006;66:718-722.
21. Urenjak J, Williams SR, Gadian DG, et al. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem. 1992;59:55-61.
22. Kantarci K, Jack CR, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology. 2000;55:210-217.
23. Catani M, Cherubini A, Howard R, et al. H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport. 2001;12(11):2315-2317.
24. Huang W, Alexander GE, Daly EM, et al. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Am J Psychiatry. 1999;156:1879-1886.
25. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 1997;56:321-329.
26. Valenzuela M, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 2001;56:592-598.
27. Szatkowski M, Attwell D. Triggering and execution of neuronal death in brain ischemia: two phases of glutamate release by different mechanisms. Trends Neurosci. 1994;17:359-365.
28. Ross B. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed. 1991;4:59-63.
29. Prost RW, Mark L, Mewissen M, et al. Detection of glutamate/glutamine resonance by 1H magnetic resonance spectroscopy at 0.5 T. Magn Reson Med. 1997;37:615-618.
30. Wellard RM, Briellmann RS, Jennings C, et al. Physiologic variability of single-voxel proton MR spectroscopic measurements at 3T. Am J Neuroradiol. 2005;26:585-590.
31. Kantarci K, Reynolds G, Petersen RC, et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. Am J Neuroradiol. 2003;24:843-849.
32. Choi A, Coupland NJ, Bhardwaj PP, et al. Measurement of brain glutamate and glutamine by spectrally-selective refocusing at 3 tesla. Magn Reson Med. 2006;55:997-1005.
33. Schubert F, Gallinat J, Seifert F, et al. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage. 2004;21:1762-1771.
34. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613-622.
35. Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders: focus on schizophrenia and Alzheimer's disease. Prog Brain Res. 1998;116:421-437.
36. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
37. Antuono PG, Jones JL, Wang J, et al. Decreased glutamate and glutamine in Alzheimer's disease detected in vivo with H-MRS at 0.5 T. Neurology. 2001;56:737-742.
38. Prost RW. Two-Dimensional Chemical Shift Imaging of Glutamate and Glutamine at 0.5 T with Application to Neurodegenerative Disease [PhD thesis]. Milwaukee, WI: Medical College of Wisconsin; 1999.
39. Braak H, Braak E. Neuropathological staging of Alzheimer's disease. Acta Neuropathol (Berl). 1991;82:239-259.
40. Fewster P, Griffin-brooks S, MacGregor J, et al. A topographical pathway by which histopathological lesions disseminate through the brain of patients with Alzheimer's disease. Dementia. 1991;2:121-132.
41. Hattori N, Abe K, Sakoda S, et al. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport. 2002;13(1):183-186.
42. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
43. Ackl N, Ising M, Schreiber YA, et al. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2005;384:23-28.
44. Chantal S, Braun CMJ, Bouchard RW, et al. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res. 2004;1003:26-35.
45. Martinez-Bisbal MC, Arana E, Marti-Bonmati L, et al. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur J Neurol. 2004;11:187-193.
46. Fox MC, Warrington EK, Freebrorough PA. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain. 1996;119:2001-2007.
47. Haxby JV, Grady CL, Koss B, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol. 1990;47:753-760.
48. Mark LP, Prost RW, Ulmer JL, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. Am J Neuroradiol. 2001;22:1813-1824.